secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH)
CIK:        0001742927
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001437749-25-019716
Event type: regulatory
Sentiment:  neutral
Materiality: 0.15
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Reviva Pharmaceuticals appoints Baker Tilly as new auditor after Moss Adams merger
--------------------------------------------------------------------------------

- Moss Adams LLP merged with Baker Tilly US, LLP effective June 3, 2025; Moss Adams resigned as auditor the same day.
- Audit Committee appointed Baker Tilly as successor independent registered public accounting firm effective June 3, 2025.
- No disagreements or reportable events occurred with Moss Adams during fiscal years 2024-2025 interim period.
- Prior audit reports included a going concern explanatory paragraph; no adverse or qualified opinions issued.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925019716/0001437749-25-019716-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1742927/000143774925019716/rvph20250605_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-019716

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer